Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Intensity-modulated radiotherapy for pancreatic adenocarcinoma.

Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, Kunz P, Norton JA, Visser BC, Poultsides GA, Koong AC, Chang DT.

Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):e595-601. doi: 10.1016/j.ijrobp.2011.09.035. Epub 2011 Dec 22.

PMID:
22197234
2.

Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.

Ben-Josef E, Shields AF, Vaishampayan U, Vaitkevicius V, El-Rayes BF, McDermott P, Burmeister J, Bossenberger T, Philip PA.

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):454-9.

PMID:
15145162
3.

Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome.

Milano MT, Chmura SJ, Garofalo MC, Rash C, Roeske JC, Connell PP, Kwon OH, Jani AB, Heimann R.

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):445-53.

PMID:
15145161
4.

Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.

Keene KS, Rich TA, Penberthy DR, Shepard RC, Adams R, Jones RS.

Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):97-103.

PMID:
15850908
5.

Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers.

Yovino S, Poppe M, Jabbour S, David V, Garofalo M, Pandya N, Alexander R, Hanna N, Regine WF.

Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):158-62. doi: 10.1016/j.ijrobp.2009.10.043. Epub 2010 Apr 14.

PMID:
20399035
6.

Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.

Han L, Lin SJ, Pan JJ, Chen CB, Zhang Y, Zhang XC, Liao XY, Chen QS.

Chin J Cancer. 2010 Feb;29(2):145-50.

7.

Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.

Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, Cameron JL, Pawlik TM, Schulick RD, Wolfgang CL, Laheru DA, Farnell MB, Swartz MJ, Gunderson LL, Miller RC.

Ann Surg Oncol. 2010 Apr;17(4):981-90. doi: 10.1245/s10434-009-0743-7. Epub 2010 Jan 20.

8.

Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer.

Jackson AS, Jain P, Watkins GR, Whitfield GA, Green MM, Valle J, Taylor MB, Dickinson C, Price PM, Saleem A.

Clin Oncol (R Coll Radiol). 2010 Sep;22(7):570-7. doi: 10.1016/j.clon.2010.06.007. Epub 2010 Jul 21.

PMID:
20650619
9.

Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma.

Chakravarty T, Crane CH, Ajani JA, Mansfield PF, Briere TM, Beddar AS, Mok H, Reed VK, Krishnan S, Delclos ME, Das P.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):581-6. doi: 10.1016/j.ijrobp.2011.07.035. Epub 2011 Dec 2.

PMID:
22137021
10.

Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience.

de Arruda FF, Puri DR, Zhung J, Narayana A, Wolden S, Hunt M, Stambuk H, Pfister D, Kraus D, Shaha A, Shah J, Lee NY.

Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):363-73. Epub 2005 May 31.

PMID:
15925451
11.

Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival.

Ogawa K, Ito Y, Hirokawa N, Shibuya K, Kokubo M, Ogo E, Shibuya H, Saito T, Onishi H, Karasawa K, Nemoto K, Nishimura Y; Japanese Radiation Oncology Study Group Working Subgroup of Gastrointestinal Cancers.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):559-65. doi: 10.1016/j.ijrobp.2011.07.013. Epub 2011 Oct 20.

PMID:
22019243
12.
13.

Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy.

Schoenfeld JD, Sher DJ, Norris CM Jr, Haddad RI, Posner MR, Balboni TA, Tishler RB.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):308-14. doi: 10.1016/j.ijrobp.2010.09.042. Epub 2010 Nov 13.

PMID:
21075557
14.

Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.

Baschnagel A, Shah C, Margolis J, Nadeau L, Stein J, Jury R, Robertson JM.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e331-5. doi: 10.1016/j.ijrobp.2012.01.008. Epub 2012 Mar 13.

PMID:
22420967
15.

Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study.

Passoni P, Reni M, Cattaneo GM, Slim N, Cereda S, Balzano G, Castoldi R, Longobardi B, Bettinardi V, Gianolli L, Gusmini S, Staudacher C, Calandrino R, Di Muzio N.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1000-6. doi: 10.1016/j.ijrobp.2013.09.012.

PMID:
24267968
16.

Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone.

Su SF, Han F, Zhao C, Chen CY, Xiao WW, Li JX, Lu TX.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):327-33. doi: 10.1016/j.ijrobp.2010.09.011. Epub 2010 Oct 29.

PMID:
21035959
17.

Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine.

Allen AM, Zalupski MM, Robertson JM, Eckhauser FE, Simone D, Brown D, Hejna G, Normolle D, Lawrence TS, McGinn CJ.

Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1461-7.

PMID:
15275733
18.

Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.

Chakravarthy A, Abrams RA, Yeo CJ, Korman LT, Donehower RC, Hruban RH, Zahurek ML, Grochow LB, O'Reilly S, Hurwitz H, Jaffee EM, Lillemoe KD, Cameron JL.

Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1089-96.

PMID:
11072167
19.

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB.

Ann Surg Oncol. 2001 Mar;8(2):123-32.

PMID:
11258776
20.

Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer.

Samuelian JM, Callister MD, Ashman JB, Young-Fadok TM, Borad MJ, Gunderson LL.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1981-7. doi: 10.1016/j.ijrobp.2011.01.051. Epub 2011 Apr 7.

PMID:
21477938

Supplemental Content

Support Center